Introduction {#Sec1}
============

The medical treatment of male lower urinary tract symptoms (LUTS) typically consists primarily of α~1~-adrenoceptor antagonists, but in many patients this provides insufficient symptom relief. A combination of α~1~-adrenoceptor and muscarinic receptor antagonists may be more effective, particularly against storage symptoms \[[@CR1], [@CR2]\]. While most combination studies have used tolterodine as the muscarinic antagonist, several have also been based on propiverine \[[@CR1]--[@CR4]\].

Propiverine is an antagonist with similar affinity for all muscarinic receptor subtypes \[[@CR5], [@CR6]\] which also inhibits voltage-gated L-type Ca^2+^-channels \[[@CR9]--[@CR13]\]. As contractions of prostate \[[@CR7]\] and bladder smooth muscle \[[@CR8]\] at least partly depend on such channels, their inhibition may contribute to the therapeutic effects of propiverine in LUTS suggestive of benign prostatic hyperplasia and overactive bladder (OAB), respectively.

Based upon the growing interest in a combination treatment of male LUTS, we have explored possible α~1~-adrenoceptor antagonist effects of propiverine and its metabolites M-5, M-6, and M-14, which share the anti-muscarinic and/or L-type Ca^2+^-channel-blocking activity of propiverine \[[@CR16], [@CR17]\].

Materials and methods {#Sec2}
=====================

Prostate and trigone detrusor contraction {#Sec3}
-----------------------------------------

Human prostate was obtained with informed written consent in accordance with the regulations of the local hospital ethical committee (permit EK 194092004) from six patients undergoing combined prostectomy and radical cystectomy for invasive bladder cancer (65 ± 3 years). Urinary bladder trigone from juvenile and adult female pigs were obtained from a local abattoir. Prostate strips (10 mm long and 3--4 mm wide) and trigone strips (7--10 mm long and 2--4 mm wide without urothelium) were prepared and mounted in organ baths as previously described \[[@CR7], [@CR18]\] except for a resting load of 5 mN. After an equilibration period of 60 min, the strips were challenged with a single concentration of α~1~-adrenoceptor agonist phenylephrine (10 μM) to reach a stable pre-contraction after 60 min. Then, increasing concentrations of test compounds were added cumulatively (15 min between concentration steps). Relaxation values were normalized to the 10 μM forskolin effect, as determined at the end of each experiment, and were corrected for spontaneous decline of force in time-matched control (TMC) experiments.

In other experiments, porcine trigone strips were exposed to cumulatively increasing concentrations of phenylephrine (30 nM--100 μM) with 5 min of stabilization between two subsequent additions. After maximum contraction was observed, phenylephrine was removed by washing 3 times with drug-free solution and re-equilibrating for 60 min. Then a single concentration of test compound was added and after additional 30 min, a second concentration-response curve for phenylephrine was generated.

Radioligand binding {#Sec4}
-------------------

Binding of propiverine and its metabolites to human α~1~-adrenoceptor subtypes was analyzed in Chinese hamster ovary (CHO) cells, expressing approximately 2 pmol receptor/mg protein, by competition binding against \[^3^H\]-prazosin as previously described \[[@CR19], [@CR20]\]. Phentolamine was used as a reference antagonist. Radioactivity adherent to the filters was quantified in a Topcount NXT (Perkin Elmer, Zaventem, Belgium) using Microsint O (Perkin Elmer) scintillator.

Intracellular Ca^2+^ {#Sec5}
--------------------

Cells were plated in black, clear bottom 96 wells plates at 50,000 cells per well. After 24 h in serum-free medium, cells were loaded for 1 h with 4 μM Fluo-4 AM ester in buffer (HBSS containing 20 mM HEPES and 250 mM probenecid and 0.42% v/v pluronic acid). They were then washed twice and incubated for 45 min with buffer. Fluorescence was measured using an excitation filter at 485 nm and emission filter at 520 nm on a NOVOstar (BMG Labtech, via Isogen, IJselstein, the Netherlands). After measuring the basal level for 10 s, phenylephrine (100 pM--10 μM) was added and measured for 50 s, then 5% v/v triton X-100 in basic buffer was added at 10% v/v to determine the maximal signal (F~max~). After 20 s, 0.1 M EGTA in buffer was added at 10% v/v to determine the minimal signal (F~min~). The increase in free intracellular Ca^2+^ (\[Ca^2+^\]~i~) was calculated as the difference between the \[Ca^2+^\]~i~ for the basal level and after adding a ligand. \[Ca^2+^\]~i~ was calculated by the equation:$$\documentclass[12pt]{minimal}
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*K*~*d*~ is the dissociation constant of the binding of Fluo-4 to Ca^2+^ (345 nM). Concentration-response curves for phenylephrine were generated in duplicate in the absence and presence of propiverine, its metabolites M-5, M-6, and M-14 and the reference antagonist phentolamine (added 15 min prior to phenylephrine).

Data analysis {#Sec6}
-------------

Experimental data were analyzed, by non-linear curve fitting of each individual experiment using GraphPad Prism^®^ 4.00 (GraphPad Software, San Diego, CA, USA). Potencies of propiverine, tamsulosin, and prazosin on phenylephrine pre-contracted human prostate and porcine trigone strips were determined as −log IC~50~ \[M\] values. The potency (−log EC~50~ \[M\]) and efficacy of phenylephrine-induced contractions and \[Ca^2+^\]~i~ elevations were determined in the absence and presence of the indicated test compounds. Maximum contraction during the second concentration-response curve for phenylephrine (Eff~max~) was expressed as percent of the maximum effects during the first concentration-response curve (=100%). Inhibitory potency as determined from competition binding experiments was transformed to −log *K*~i~ values using the Cheng and Prusoff equation. Statistical differences were tested by Student's *t-*test and were considered significant for *P* \< 0.05.

Chemicals {#Sec7}
---------

\[^3^H\]-prazosin (specific activity 80 Ci/mmol) was purchased from Perkin Elmer (Zaventem, Belgium). Propiverine hydrochloride, M-5 (2,2-diphenyl-2-propoxy-acetic acid \[1-methyl-piperid-4-yl\]-ester-N-oxide-trans), M-6 (2,2-diphenyl-2-hydroxy-acetic acid \[1-methyl-piperid-4-yl\]-ester-N-oxide-trans), M-14 (2,2-diphenyl-2-propoxy-acetic acid \[piperid-4-yl\]-ester), and tamsulosin were synthesized at APOGEPHA Arzneimittel GmbH. Prazosin was from TOCRIS (Bristol, UK). Fluo-4 AM ester and pluronic acid were from Molecular Probes (via Invitrogen, Breda, The Netherlands). Phentolamine, phenylephrine, and all other chemicals were from SIGMA--ALDRICH (Taufkirchen, Germany).

Results {#Sec8}
=======

Effects on α~1~-adrenoceptor-mediated prostate contraction {#Sec9}
----------------------------------------------------------

At the end of the equilibration period, human prostate strips exhibited a passive tension of 0.06 ± 0.01 mN/mg wet weight (*n* = 16 strips/five patients). Phenylephrine (10 μM) increased force of contraction to peak values of 0.16 ± 0.02 mN/mg (*n* = 19/6), which stabilized at steady-state values of 0.10 ± 0.02 mN/mg (*n* = 16/5) within 45 min (Fig. [1](#Fig1){ref-type="fig"}a). The maximum relaxation induced by 10 μM forskolin was 0.07 ± 0.01 mN/mg (*n* = 16/5). Propiverine, tamsulosin, and prazosin relaxed phenylephrine-induced contractions in a concentration-dependent manner (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1**a** Original recordings of force of contraction in a human prostate tissue strip. The preparation was pre-contracted with phenylephrine (PE, 10 μM) (*left arrow*). After stabilization of force, propiverine or vehicle were added in increasing concentrations (0.1--100 μM). Finally, forskolin (10 μM) was added for complete relaxation. The difference between force prior to addition of the test compound and force in the presence of forskolin was taken as maximum relaxation (=100%). **b** Effects of tamsulosin, prazosin, and propiverine on α~1~-adrenoceptor-mediated contractions in the human prostate (calculated --log IC~50~ values 10.39 ± 0.04, 7.73 ± 0.04, and 4.43 ± 0.08, respectively). Values were corrected for spontaneous relaxation during time-matched controls, normalized to percent relaxation by forskolin and expressed as means ± SEM

Effects on α~1~-adrenoceptor-mediated trigone contraction {#Sec10}
---------------------------------------------------------

Phenylephrine concentration-dependently contracted adult porcine trigone (but not bladder wall) with maximum contractions of 1.24 ± 0.23 mN/mg wet weight and a −log EC~50~ \[M\] of 5.74 ± 0.04 (*n* = 6). In juvenile tissues, these contractions were concentration-dependently reversed by tamsulosin, prazosin, and propiverine (Fig. [2](#Fig2){ref-type="fig"}a). The overall relaxing effect of propiverine on contractions was similar in tissue from mature and juvenile animals, but the potency was lower in mature than in juvenile pigs (−log IC~50~ \[M\] 5.01 ± 0.05 vs. 6.21 ± 0.10, respectively; *n* = 5--7; *P* \< 0.05; Fig. [2](#Fig2){ref-type="fig"}a,b). In trigone from mature pigs M-14 caused similar relaxation when compared to propiverine but with lower potency (4.84 ± 0.08; *n* = 8; Fig. [2](#Fig2){ref-type="fig"}b). M-5 and M-6 did not influence trigone contractions in concentrations up to 100 μM (data not shown).Fig. 2**a** Effects of cumulatively added concentrations of phenylephrine on adult pig detrusor tissue from the trigone and the wall area of the urinary bladder. Data were normalized to mN/mg wet weight of the detrusor strip. **b** Effects of increasing concentrations of propiverine in comparison to those of the α~1~-adrenoceptor antagonists tamsulosin and prazosin on juvenile porcine detrusor strips from the trigone area of the urinary bladder. Strips were pre-contracted with 10 μM of the α~1~-adrenoceptor agonist phenylephrine. **c** Effects of increasing concentrations of propiverine and its metabolites M-5 and M-6 and **d** effects of propiverine and M-14 on trigone detrusor strips from mature pigs pre-contracted with phenylephrine (10 μM). Data in **b**--**d** were normalized to percent relaxation by forskolin (10 μM) and corrected for spontaneous relaxation during time-matched controls. Means ± SEM

Concentration-response curves for phenylephrine in porcine trigone strips in the presence of increasing propiverine concentrations demonstrated that inhibition was largely insurmountable, i.e., mainly consisting of reduced maximum responses with only minor if any reductions in apparent potency (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Effect of increasing concentrations of propiverine on concentration-response curves for phenylephrine in adult porcine detrusor strips from the trigone area. Each strip underwent one phenylephrine curve in the absence of propiverine, and the result maximum response was defined as 100%. Then, phenylephrine response curves were repeated in the absence (time-matched control, TMC) and presence of 10, 30, and 100 μM propiverine yielding phenylephrine potencies (−log EC~50~) of 5.82 ± 0.19, 5.46 ± 0.38, 5.48 ± 0.28, and 5.90 ± 0.22, respectively. Corresponding Eff~max~ values were 58 ± 9, 39 ± 6, 28 ± 6\*, and 9 ± 2\*\* (expressed as % of values in corresponding first phenylephrine curve; \* and \*\*: *P* \< 0.05 and \< 0.01, respectively, vs. TMC). Means ± SEM from 5--8 experiments

Binding to α~1~-adrenoceptor subtypes {#Sec11}
-------------------------------------

Direct α~1~-adrenoceptor inhibition was evaluated in radioligand binding assays with CHO cells. Propiverine, M-14, and phentolamine competed for \[^3^H\]-prazosin binding with −log K~i~ values of 4.72 ± 0.01, 4.72 ± 0.04, and 8.62 ± 0.19 at α~1A~-, 4.94 ± 0.02, 5.02 ± 0.11 and 7.96 ± 0.22 at α~1B~-, and 4.73 ± 0.02, 4.57 ± 0.06 and 7.87 ± 0.04 at α~1D~-adrenoceptors, respectively (Fig. [4](#Fig4){ref-type="fig"}). In contrast, the metabolites M-5 and M-6 had little effect at up to 100 μM.Fig. 4Effects of propiverine and its metabolites M-5, M-6, and M-14 on \[^3^H\]-prazosin binding in human α~1A~-, α~1B~-, and α~1D~-adrenoceptor-expressing CHO cells. The α~1~-adrenoceptor antagonist phentolamine was used for comparison. Data in the presence of increasing concentrations of test compound are expressed in percent binding of \[^3^H\]-prazosin. For control experiments only DMSO was added as a vehicle. Means ± SEM from 3 experiments

α~1A~-Adrenoceptor-mediated intracellular Ca^2+^ elevation {#Sec12}
----------------------------------------------------------

The \[Ca^2+^\]~i~ increase with 10 μM phenylephrine was about 1,600 nM, and all subsequent data values are normalized to that response as measured within a given experiment (=100%). Propiverine and M-14 concentration-dependently inhibited the \[Ca^2+^\]~i~ elevations, but this inhibition largely consisted of reduced maximum responses with small if any effects on phenylephrine potency (Fig. [5](#Fig5){ref-type="fig"}a,b). M-5 or M-6 had little effect (Fig. [5](#Fig5){ref-type="fig"}c), whereas antagonism by phentolamine was surmountable (Fig. [5](#Fig5){ref-type="fig"}d).Fig. 5Phenylephrine-stimulated elevation of \[Ca^2+^\]~i~ in α~1A~-adrenoceptor-expressing CHO cells. **a** Control concentration-response curves in the presence of DMSO, and responses to increasing concentrations of propiverine. The vehicle DMSO did not significantly affect the efficacy or potency of phenylephrine to raise \[Ca^2+^\]~i~ (*n* = 4), data not shown. **b** Responses to M-14 and **c** responses to M-5 and M-6. **d** Responses to phentolamine. Data were normalized to \[Ca^2+^\]~i~ increase in the presence of 10 μM phenylephrine (=100%). Means ± SEM from 4--5 experiments

Discussion {#Sec13}
==========

Propiverine differs from most other OAB drugs as it is not only a muscarinic receptor antagonist \[[@CR5], [@CR6]\] but also inhibits L-type Ca^2+^ channels \[[@CR9]--[@CR13]\]. Based upon the increasing interest in a combination treatment of male LUTS \[[@CR14]--[@CR16]\], we have explored possible α~1~-adrenoceptor antagonism of propiverine and three of its main metabolites. The α~1~-adrenoceptor antagonists phentolamine, prazosin, and tamsulosin were used as reference compounds and exhibited the expected potency for interaction with α~1~-adrenoceptors, thereby validating our model systems and techniques. Due to limited access to human prostate specimen for organ bath experiments as well as smaller signal/noise ratios, we have used porcine trigone as a well established animal model of α~1~-adrenoceptor-mediated contraction of urological tissue for more detailed analysis.

Our data demonstrate concentration-dependent relaxation of phenylephrine-induced tone of human prostate and porcine trigone. At least in trigone, similar relaxation was observed with the propiverine metabolite M-14 but not with M-5 or M-6. As phenylephrine-induced contraction in these two preparations is α~1~-adrenoceptor-mediated \[[@CR17]\], this relaxation provided initial evidence for α~1~-adrenoceptor antagonism by propiverine and M-14. However, L-type Ca^2+^ channels contribute to prostate and bladder contraction \[[@CR9], [@CR10]\]. The direct interaction of propiverine and its metabolites with α~1~-adrenoceptors was demonstrated in competition binding studies with cloned human α~1~-adrenoceptor subtypes, yielding affinities in line with their potency to relax human prostate and porcine trigone. To verify that the inhibition of radioligand binding was indeed associated with receptor antagonism, concentration-dependent inhibition of phenylephrine-induced \[Ca^2+^\]~i~ elevation was demonstrated. In contrast to tissue relaxation experiments, inhibition of \[Ca^2+^\]~i~ elevation in CHO cells cannot be explained by Ca^2+^ channel-blocking properties of propiverine, because CHO cells do not express such L-type Ca^2+^ channels. Together these experiments demonstrate that propiverine and its metabolite M-14 bind to and inhibit human α~1~-adrenoceptors and accordingly can relax α~1~-adrenoceptor-mediated contraction of human prostate and porcine trigone.

Propiverine is a competitive antagonist with similar affinity for all muscarinic receptor subtypes \[[@CR5], [@CR6], [@CR11]\]. However, the antagonism of \[Ca^2+^\]~i~ elevations in CHO cells and of contraction in porcine trigone was insurmountable. Thus, the molecular interaction of propiverine with α~1~-adrenoceptors and muscarinic receptors occurs in a different way despite the drug being an antagonist for both receptor families. This differential interaction is also supported by the fact that the propiverine metabolites M-5 and M-6 lacked α~1~-adrenoceptor effects but inhibit muscarinic receptor function \[[@CR5], [@CR10], [@CR18], [@CR19]\].

The affinity of propiverine for α~1~-adrenoceptors in the present study differs from that for human M~3~ receptors by 50- to 100-fold \[[@CR5], [@CR6], [@CR12]\] but is very similar to its potency for inhibition of L-type Ca^2+^ channels \[[@CR12]\]. As muscarinic antagonists typically are dosed to yield high receptor occupancy rates \[[@CR20]\], it can be expected that therapeutic doses of propiverine exhibit some degree of α~1~-adrenoceptor antagonism and L-type Ca^2+^ channel blockade. Based upon reported plasma concentrations of propiverine (parent compound alone) \[[@CR21]\] and our affinity estimates from the radioligand binding studies, therapeutic propiverine concentrations could occupy up to 10% of α~1~-adrenoceptors. While this may be less pronounced than the blockade of muscarinic receptors, it may nevertheless contribute to the clinical profile of propiverine and specifically may be beneficial for the treatment of male LUTS. Moreover, the insurmountable antagonism at α~1~- (but not muscarinic) receptors raises the possibility that even limited α~1~-adrenoceptor occupancy will yield considerable inhibition over time. Interestingly, a large recent observational study reported that the clinical effects of propiverine against OAB symptoms were quantitatively similar in men when administered alone or as add-on to an existing α-blocker treatment \[[@CR22]\]. While these findings do not prove α~1~-antagonism of propiverine in vivo, they are in line with this proposal. However, dedicated studies will be required to determine the clinical relevance of such effects. They should also take into account that propiverine and its various metabolites differ in their in vivo plasma concentrations \[[@CR23]\]. For each of them, the relative contribution of the three molecular targets may differ in the generation of bladder selectivity and the overall relaxing effect in the lower urinary tract \[[@CR24]\]. Even if propiverine itself turns out to have too little α~1~-antagonism in vivo, it is an exciting starting point for the future synthesis of balanced α~1~/muscarinic receptor antagonists.

Conclusions {#Sec14}
===========

In contrast to other drugs used for the treatment of OAB, propiverine is not only a muscarinic receptor antagonist but also has L-type Ca^2+^ channel blocking and α~1~-adrenoceptor antagonist effects. While each of these effects may be beneficial in the treatment of voiding dysfunction, including male LUTS, the relative contribution of these mechanisms and of the propiverine metabolites to the overall therapeutic effects upon oral administration of propiverine remains to be determined.
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